Reference/GLP-1 receptor agonist

Semaglutide

GLP-1 Receptor Agonist · Weight Loss & Diabetes

Human preliminary

research use only

Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant efficacy through appetite suppression and glycemic control. The 7-day half-life enables convenient weekly dosing.

15-20% average body weight reductionEstablished cardiovascular protectionConvenient once-weekly dosing optionsComprehensive safety data from extensive trials

9 citations·4 with human data·Updated 10 Aug 2026

Overview

Mimics native GLP-1, binding to receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic pathways.

Evidence profilederived from 9 references

Human preliminary

Strongest design among the references on this page. Grade and effect size are separate facts and are never merged into one score.

Research indications

What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.

Weight Loss3

Clinically Significant Weight Reduction

FDA-approved for chronic weight management with average 15-20% body weight loss in clinical trials.

Large

Appetite and Craving Control

Reduces hunger and food cravings through central nervous system GLP-1 receptor activation.

Large

Sustained Weight Maintenance

Long-term studies show maintained weight loss with continued treatment over 2+ years.

Moderate

Diabetes3

Glycemic Control

FDA-approved for type 2 diabetes with HbA1c reductions of 1.5-2% in clinical trials.

Large

Cardiovascular Protection

Proven 26% reduction in cardiovascular death, MI, or stroke in high-risk diabetes patients.

Large

Beta Cell Preservation

Improves insulin secretion and may preserve pancreatic beta cell function.

Moderate

Metabolic3

Metabolic Syndrome Improvement

Addresses multiple components: weight, glucose, blood pressure, and lipids.

Moderate

NASH/Fatty Liver

Emerging evidence for improvements in non-alcoholic fatty liver disease.

Small

Inflammation Reduction

Decreases systemic inflammation markers independent of weight loss.

Small

A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.

Quick factsreference only

Class: GLP-1 receptor agonist
Chain length: 31 residues
Molecular weight: 4113.64 Da
Half-life: ~168 h
Typical dose: 0.25mg starting, titrate to 1-2.4mg weekly
Frequency: Once weekly (same day each week)
Cycle length: Ongoing therapy as prescribed
Storage: Pen: 2-8°C before first use, room temp up to 56 days after. Compounded: 2-8°C

Molecular data

Type: GLP-1 receptor agonist
Molecular weight: 4113.64 Da
Chain length: 31 residues
Half-life: 10080 min

Dosing reference

Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.

Context	Route	Amount	Frequency
Weight Loss Initiation	Subcutaneous	0.25mg	Weekly x 4 weeks, then increase
Weight Loss Maintenance	Subcutaneous	2.4mg	Weekly (after 16-week titration)
Diabetes Management	Subcutaneous	0.5-1mg	Weekly
Cardiovascular Protection	Subcutaneous	0.5-1mg	Weekly
Tolerability-Based	Subcutaneous	0.25-2.4mg	Weekly (individualized)
Diabetes Initiation	Oral (empty stomach)	3mg	Daily x 30 days
Standard Diabetes Dose	Oral (empty stomach)	7mg	Once daily
Maximum Diabetes Dose	Oral (empty stomach)	14mg	Once daily

Interactions

Insulin

May increase hypoglycemia risk when combined; requires blood glucose monitoring.

monitor

Tirzepatide

Both are incretin mimetics with overlapping mechanisms; concurrent use increases side effects.

avoid

Cagrilintide

Combined as CagriSema in clinical trials for enhanced weight loss efficacy.

synergistic

Metformin

Commonly used together for diabetes management with good safety profile.

compatible

BPC-157

No contraindications; may help with GI side effects.

compatible

Sulfonylureas

Increased hypoglycemia risk; may require sulfonylurea dose reduction.

monitor

Oral Medications

Delayed gastric emptying may affect absorption of oral medications.

monitor

Quality checklist

✓FDA-approved branded products (Ozempic, Wegovy, Rybelsus)
✓Proper refrigeration verified and not expired
✓Clear, colorless to slightly yellow solution in pen/vial
!Compounded versions - FDA warns about untested compounded semaglutide
×Cloudy or discolored solution
×Particles or precipitation visible
×Non-pharmacy sources or unverified online sellers

What to expect

Week 1-4Mild appetite reduction, possible nausea during initial dose

Month 2-3Noticeable weight loss (5-10% typical), improved satiety

Month 4-6Continued weight loss (10-15% common), stable glucose levels

Month 6+Weight loss plateau possible, focus on maintenance

DiabetesBlood sugar improvements within 1-2 weeks

Safety

Commonly reported5

Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain

Stop and seek advice7

Severe persistent abdominal pain (possible pancreatitis)
Persistent vomiting preventing fluid intake
Signs of thyroid tumor (neck lump, hoarseness, trouble swallowing)
Severe allergic reaction (rash, itching, difficulty breathing)
Vision changes (possible diabetic retinopathy progression)
Severe hypoglycemia (if combined with insulin/sulfonylureas)
Kidney problems (decreased urination, swelling)

Contraindications4

Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis

FAQ

Does semaglutide prevent weight regain after you stop taking it?

No. Long-term studies show sustained weight loss only while continuing treatment. After discontinuation, weight typically returns. This means semaglutide is likely a long-term maintenance therapy, not a temporary reset. Phase 3 trials (2+ years of data) confirm the need for ongoing use to maintain weight loss.

Why does semaglutide help heart disease even without diabetes?

The SELECT trial (17,604 people) proved semaglutide reduces cardiovascular events by 20% in obese people without diabetes. The mechanism involves inflammation reduction, improved lipid profiles, blood pressure lowering, and hepatic fat reduction—benefits that protect the heart independent of glucose control.

Can I use oral Rybelsus instead of injections to avoid needles?

Yes, but with caveats. Rybelsus tablets require very strict administration (empty stomach, no food/meds for 30 minutes, specific water volume). Its bioavailability is lower than injections, so you need higher doses (7-14mg vs 0.5-2.4mg weekly for injections). Many people prefer injections despite the needle because they're more forgiving.

Is semaglutide's weight loss real fat loss or mostly water/muscle?

Mostly real fat loss. Clinical trials show semaglutide reduces fat mass substantially with lean mass preservation (similar ratio to other weight loss treatments). The 15-20% weight loss isn't just water—it's sustained fat reduction. However, some lean mass loss does occur, which is why resistance training is recommended.

References

1
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Marso, S.P., et al. · New England Journal of Medicine · 2016
26% reduction in MACE (HR 0.74) with semaglutide vs placebo. Established cardiovascular safety and benefit profile for semaglutide in type 2 diabetes.
human-pilotPubMed 27633186 ↗
2
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6)
Husain, M., et al. · New England Journal of Medicine · 2019
Oral semaglutide was noninferior to placebo for cardiovascular safety. Numerically fewer CV deaths in oral semaglutide group (0.9% vs 1.9%).
human-pilotPubMed 31185157 ↗
3
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding, J.P.H., et al. · New England Journal of Medicine · 2021
14.9% average weight loss vs 2.4% placebo over 68 weeks with 2.4mg weekly. 86% achieved ≥5% weight loss; 51-64% achieved ≥15% weight loss.
reviewPubMed 33567185 ↗
4
Two-year effects of semaglutide in adults with overweight or obesity (STEP 5)
Garvey, W.T., et al. · Nature Medicine · 2022
Sustained weight loss of 15.2% at week 104 vs 2.6% placebo. 77.1% achieved ≥5% weight loss at 2 years, demonstrating long-term efficacy.
reviewPubMed 36216945 ↗
5
Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS)
Weghuber, D., et al. · New England Journal of Medicine · 2022
16.1% BMI reduction with semaglutide vs 0.6% increase with placebo over 68 weeks. 44.9% of semaglutide recipients reclassified to normal-weight or overweight BMI category.
reviewPubMed 36322838 ↗
6
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Lincoff, A.M., et al. · New England Journal of Medicine · 2023
20% reduction in MACE (CV death, MI, or stroke) with semaglutide 2.4mg vs placebo over mean 40 months. First GLP-1 RA to demonstrate cardiovascular benefit in non-diabetic population.
reviewPubMed 37952131 ↗
7
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)
Kosiborod, M.N., et al. · New England Journal of Medicine · 2023
Semaglutide 2.4mg reduced symptoms, physical limitations, and improved exercise function in obesity-related HFpEF. Reduced inflammation and appeared to improve adverse cardiac remodeling.
human-pilotPubMed 37622681 ↗
8
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW)
Perkovic, V., et al. · New England Journal of Medicine · 2024
24% lower risk of primary kidney outcome (kidney failure, sustained eGFR decline, or renal/CV death) with semaglutide vs placebo. 29% reduction in CV death. Trial stopped early for efficacy.
human-pilotPubMed 38785209 ↗
9
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE)
Sanyal, A.J., et al. · New England Journal of Medicine · 2025
62.9% achieved MASH resolution without fibrosis worsening vs 34.3% placebo at 72 weeks. Combined resolution and fibrosis improvement in 32.7% vs 16.1% placebo. Mean weight loss of 10.5%.
reviewPubMed 40305708 ↗